Case Studies

Identifying market access influence to increase the value of life science advisory boards and engagements

A clinical team wanted to design a Phase III trial for a new therapy used to treat a rare disease. To gauge economic viability, the team needed to understand how global payer organizations would weigh the benefits of the therapy and where the treatment might be placed in formularies.

Using asynchronous engagement to gain patient perspectives in pharma, amplify patient voices, and protect patient privacy.

Congress social monitoring helps pharma teams find new experts, drive more productive conversations, and make more informed decisions.

A post-market advisory board helped a medical affairs team identify new opportunities for differentiation. Read the case study to learn more.

A HEOR virtual advisory board enabled a medical affairs team to develop a cost-effectiveness model. Read the success story to learn how.